Post-menopausal women with atherosclerosis need to take the correct timing for hormone replacement therapy.

Accumulation of iron with age may inhibit the benefits of hormone replacement therapy on cardiovascular disease in late postmenopause.

A drug used in hormone replacement therapy can target estrogen receptors that have become resistant to breast cancer treatments.

Younger age at diagnosis of breast cancer was associated with higher risks of incident myocardial infarction and heart failure.

Bazedoxifene's SERD activities enable it to resist the impact of activating ESR1 mutations in breast cancer.

Mirroring human patients with ARID1B mutations, Arid1b haploinsufficient mice exhibited numerous neuropsychiatric defects and revealed IGF1 deficiency related growth impairment that could be ameliorated with growth hormone supplementation.

Three new protein markers of testosterone action identified by us, may prove to be valuable as clinical tools in identifying men with testosterone deficiency and in monitoring androgen replacement therapy.

Long-term increased testosterone improved body composition and bone density, but lowered HDL and raised risks of hypertension, androgenic alopecia, prostate cancer, and spinal stenosis in males.

Parathyroid hormone attenuates osteoarthritis pain and joint degeneration by modification of subchondral bone remodeling and could be a potential disease-modifying therapy for osteoarthritis.

Heat shock factor 1 is involved in estrogen-induced chromatin remodeling in estrogen receptor-positive breast cancer cells.